Acute myeloid leukemia with IDH1 and IDH2 mutations: 2021 treatment algorithm.

Abstract excerpt

Acute myeloid leukemia is a genetically heterogeneous hematologic malignancy; approximately 20% of AML harbors a mutation in the isocitrate dehydrogenase (IDH) genes, IDH1 or IDH2. These recurrent mutations in key metabolic enzymes lead to the production of the oncometabolite 2-hydroxyglutarate, which promotes leukemogenesis through a block in normal myeloid differentiation. Since this discovery, selective oral...

Topics

Join the communities discussing this publication.

• Acute Myeloid Leukemia Research
• Algorithms
• Cancer Genomics and Diagnostics
• Histone Deacetylase Inhibitors Research
• Isocitrate Dehydrogenase